Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT06868667

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Aomori, Japan
  • GSK Investigational Site Fukuoka, Japan
  • GSK Investigational Site Himeji, Japan
  • GSK Investigational Site Kamakura, Japan
View all 16 locations
View Trial Details
Active, Not Recruiting

EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy

NCT04921787

Conditions
Chemically-Induced Disorders, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations
  • Boston University Boston, Massachusetts, United States
  • Hennepin Healthcare Research Institute Minneapolis, Minnesota, United States
  • New York University New York, United States
  • Oregon Health & Science University Portland, Oregon, United States
View Trial Details
Active, Not Recruiting

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT04246047

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Yuma, Arizona, United States
  • GSK Investigational Site Denver, Colorado, United States
  • GSK Investigational Site Kansas City, Kansas, United States
  • GSK Investigational Site Fairfield, Ohio, United States
View all 69 locations
View Trial Details
Active, Not Recruiting

China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT06868654

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Beijing, China
  • GSK Investigational Site Changchun, China
  • GSK Investigational Site Guangzhou, China
  • GSK Investigational Site Hangzhou, China
View Trial Details
Active, Not Recruiting

AG-120 in People With IDH1 Mutant Chondrosarcoma

NCT04278781

Conditions
Chondrosarcoma, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3, +14 more
Locations
  • Johns Hopkins Hospital (Data Collection Only) Baltimore, Maryland, United States
  • Columbia University (Specimen Analysis Only) New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • The Ohio State University (Data Collection Only) Columbus, Ohio, United States
View Trial Details

Related conditions